title: Percutaneous absorption of co-administered N-methyl-2-[14C]pyrrolidinone and 2-[14C]pyrrolidinone in the rat.
abstract: The percutaneous absorption has been investigated in rats of a mixture (3:2, w/w) of N-methyl-2-pyrrolidinone (NMP) and 2-pyrrolidinone (2-P), a combination intended for use as a vehicle in the formulation of an antimycotic drug to enhance skin penetration on dermal application, following co-administration of the two 14C-radiolabelled compounds by the dermal and oral routes. Radioactivity was excreted predominantly in the urine after either route of administration, and comparison of the respective excretion profiles indicated that about three-quarters of the applied dose was absorbed through the skin. Plasma concentrations of each parent compound, as determined by radio-HPLC, reached peak values at 2 hr after oral dosing, and remained relatively uniform during 1-6 hr after application to the skin, suggesting constant percutaneous absorption during this period. NMP appeared to be absorbed through the skin more extensively and at a slightly faster rate than 2-P; total percutaneous absorption tended to be more extensive in female than in male rats. Together, these two 14C-compounds accounted for most of the plasma radioactivity up to 6-8 hr post-administration. However, by 12 hr (when plasma levels were relatively low), most of the radioactivity was associated with unknown polar metabolites. In view of the extensive percutaneous absorption and little first-pass metabolism of the two pyrrolidinones, the oral route was considered to represent a valid alternative to the dermal route for the assessment of the systemic toxicity of the two compounds.
authors.affiliation: Huntingdon Research Centre Ltd, UK.
authors.forename: I
authors.initials: I
authors.lastname: Midgley
authors.forename: A J
authors.initials: AJ
authors.lastname: Hood
authors.forename: L F
authors.initials: LF
authors.lastname: Chasseaud
authors.forename: C J
authors.initials: CJ
authors.lastname: Brindley
authors.forename: S
authors.initials: S
authors.lastname: Baughman
authors.forename: G
authors.initials: G
authors.lastname: Allan
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002250:Carbon Radioisotopes; D002851:Chromatography, High Pressure Liquid; D005260:Female; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D012869:Skin Absorption; D013723:Teratogens / Q000493:pharmacokinetics*
chemical_list: D002250:Carbon Radioisotopes; D011760:Pyrrolidinones; D013723:Teratogens; C038678:N-methylpyrrolidone; C028537:2-pyrrolidone